Eli Lillys retatrutide , a triple GIP/GLP-1/glucagon agonist, showed 28.7% weight loss in Phase 3 (December 2025 results) and may be submitted to FDA in late 2026
Molecular identification and cellular localisation of GSH synthesis, uptake, efflux and degradation pathways in the rat ciliary body
Endothelial responses in Sepsis
CJC-1295/Ipamorelin is preferred for healthy aging research and optimization protocols, but MK-677s constant anabolic signaling makes it more appropriate for cachexia or wasting syndrome models
Ozempic (semaglutide) is a GLP-1 receptor agonist used for type 2 diabetes management, administered as a once-weekly subcutaneous injection
% Of patients waited 5 years or more for diagnosis % Of patients were initially misdiagnosed % Of patients are unhappy with their treatment Upcoming Events Become a Member of the Pernicious Anaemia Society With your help we can continue to do our valuable work, supporting those that need it and campaigning to secure future improvements in detection and treatment of this illness
